BioLineRx (BLRX) Tops Q1 EPS by 10c

BioLineRx (NASDAQ: BLRX) reported Q1 EPS of $0.00, $0.10 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $260 thousand versus the consensus estimate of $3.96 million.

For earnings history and earnings-related data on BioLineRx (BLRX) click here.

You May Also Be Interested In

• Morgan Stanley Downgrades Sands China Ltd. (1928:HK) (SCHYY) to Equalweight
• JPMorgan Upgrades Sika AG (SIKA:SW) (SKFOF) to Neutral
• Evercore ISI Downgrades TE Connectivity (TEL) to In Line